glp-1 news today obesity drug updates What is the pipeline for future medications for obesity? New research is challenging long-held

Its going to be a big game changer, one local bariatric surgeon says "It's going to be a big game changer," said Dr

10.1210/me.2014-1103 103 RosenstockJ.Aguilar-SalinasC.KleinE.NepalS.ListJ.ChenR.et al

After behavioral and molecular tests, experimental findings include: Cognitive improvement reduced oxidative stress Alleviation of burden tau proteins and amyloid plaques Observational Studies: These highlighted a 0.20% incidence rate in GLP-1 users compared to 0.44% in non-users, showing a lower dementia risk in patients with type 2 diabetes mellitus and obesity after treatment

It is much more subtle than filler

Mourier, A., Gautier, J